Last reviewed · How we verify
Recombinant Human Plasma Gelsolin
At a glance
| Generic name | Recombinant Human Plasma Gelsolin |
|---|---|
| Also known as | rhu-pGSN |
| Sponsor | BioAegis Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) (PHASE2)
- Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers (PHASE2)
- A Study to Evaluate Plasma Gelsolin in Healthy Volunteers (PHASE1)
- Rhu-pGSN for Severe Covid-19 Pneumonia (PHASE2)
- A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP (PHASE1, PHASE2)
- Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Human Plasma Gelsolin CI brief — competitive landscape report
- Recombinant Human Plasma Gelsolin updates RSS · CI watch RSS
- BioAegis Therapeutics Inc. portfolio CI